In vitro treatment of human acute lymphocytic leukemia cells in bone marrow with a cocktail of monoclonal antibodies.
Human leukemic cells which bear antigens present on the common acute lymphocytic leukemia (ALL) cell surface can be lysed with murine monoclonal antibodies and baby rabbit complement. With NALM-6 cells used as target cells, the optimal conditions for completely eliminating the cells in vitro have been defined. The antibody cocktail plus complement is more effective than any single antibody plus complement in lysing the target cells. Optimal lysis is obtained when the antibody cocktail at 10 micrograms/ml for each antibody and baby rabbit complement at a final dilution of 1:6 are used. Leukemic cells from two newly diagnosed ALL patients were also effectively killed by this treatment. Of special interest is the finding that human complement can be used in place of baby rabbit complement.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001853:Bone Marrow / Q000276:immunology / Q000473:pathology*; D002460:Cell Line; D003165:Complement System Proteins / Q000276:immunology; D003602:Cytotoxicity, Immunologic; D006801:Humans; D007945:Leukemia, Lymphoid / Q000628:therapy*; D051379:Mice; D011817:Rabbits
D000911:Antibodies, Monoclonal; D003165:Complement System Proteins